Kala-azar (visceral leishmaniasis) and HIV coinfection in Bihar, India: Is this combination increasing? [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 572-573

  Thakur, Chandreshwar Prasad ^a   Narayan, Shyam ^a   Ranjan, Alok ^a   Sansthan, Balaji Utthan ^a  

^a Research Institute of Medical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; NEVIRAPINE; STIBOGLUCONATE SODIUM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; COMORBIDITY; DISEASE PREDISPOSITION; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LETTER; PRIORITY JOURNAL; SKIN LEISHMANIASIS;

ADOLESCENT; ADULT; ANIMALS; CHILD; FEMALE; HIV INFECTIONS; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE;

EID: 0037446441     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00017     Document Type: Letter

References (11)

1. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999;12:62-68.
2. Thakur CP, Pandey AK, Sinha GP, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first line drug. An observational study of 80 cases. Ann Trop Med Parasitol. 1998;39:314-316.
3. Sundar S, More K, Singh DK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Report from the center of the Indian epidemic. Clin Infect Dis. 2000;31:1104-1107.
4. WHO Fact Sheet Number 116. Revised May 2000:2-3.
5. Thakur CP, Sinha PK, Singh RK, et al. Miltefosine in a case of visceral leishmaniasis with HIV co-infection and rising incidence of this disease in India. Trans R Soc Trop Med Hyg. 2000;94:696-697.
6. Olliaro P, Jha TK. Clarification of comments on trial of aminosidine in visceral leishmaniasis [letter]. BMJ. 1998;317:1250.
7. Sundar S, Goyal AK, More DK, et al. Treatment of antimony unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin B lipid complex. Ann Trop Med Parasitol. 1998; 92:755-764.
8. Thakur CP, Sinha GP, Pandey AK. Comparison of regimens of amphotericin B deoxycholate in kala-azar. Indian J Med Res. 1996; 103:259-263.
9. Nantulya V, Green E. What accounts for Uganda's remarkable HIV prevalence and incidence decline? Presented at seminar at Harvard University Center for Population and Development Studies, Cambridge, May 2002.
10. Stover J, Walker N, Garnette GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet. 2000; 360:73-77.
11. NIH Consensus Statement. National Institutes of Health Consensus Conference on Interventions to Prevent HIV Risk Behaviors, Bethesda, February 1997.